David Cheishvili (He/Him)

Chief Innovation Officer, HKG Epitherapeutics
  • Hong Kong

About David Cheishvili

An epigenetics and molecular biology professional with 25+ years of work experience in academic, public and private sectors. Holds PhD in biochemistry and currently serves chief innovation officer at HKG Epitherapeutics (Hong Kong), and as an affiliate member (McGill university, Canada).

Popular Content


Channels contributed to:

Behind the Paper

Recent Comments

Jun 13, 2023
Replying to Aoife Gahlawat

Great work, is this very specific to HCC? Have you tested other caner types`?

Thank you for your kind words and for your interest in our work. This high-throughput test has been specifically developed for the early detection of Hepatocellular Carcinoma (HCC). To ensure its specificity to HCC, the assay underwent testing on individuals with 15 different non-HCC cancers (Fig. 5, 6 and 7 of the manuscript). 


Online Elsewhere